Qiagen study shows additional utility of QuantiFERON-TB Gold Plus

Qiagen has announced that its QuantiFERON-TB Gold Plus tuberculosis test has had its clinical utility supported by two new studies.

The peer-reviewed trials have indicated that the fourth-generation test, which uses enhanced QuantiFERON technology to detect latent tuberculosis infections, can offer additional benefits thanks to its novel CD8+ T-cell stimulating antigens.

A study led by the Stanford University School of Medicine highlighted the performance of the test among healthcare workers, showing how Qiagen's product was able to increase the product's specificity in low-risk populations.

Meanwhile, the second study – led by the National Hospital Organization Hokkaido Medical Center – provided the first evidence supporting QuantiFERON-TB Gold Plus as a potential monitoring aid during treatment of active tuberculosis.

Dr Masae Kawamura, senior director for tuberculosis medical and scientific affairs at Qiagen, said: "These studies add to a growing body of clinical evidence on QuantiFERON-TB Plus, suggesting added utility for our novel CD8+ T-cell technology."

Use of QuantiFERON-TB screening solutions continues to grow rapidly, with a total of more than 30 million tests conducted worldwide to date.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.